CA2183881A1 - Pharmaceutical Excipient Having Improved Compressibility - Google Patents

Pharmaceutical Excipient Having Improved Compressibility

Info

Publication number
CA2183881A1
CA2183881A1 CA2183881A CA2183881A CA2183881A1 CA 2183881 A1 CA2183881 A1 CA 2183881A1 CA 2183881 A CA2183881 A CA 2183881A CA 2183881 A CA2183881 A CA 2183881A CA 2183881 A1 CA2183881 A1 CA 2183881A1
Authority
CA
Canada
Prior art keywords
silicon dioxide
microcrystalline cellulose
excipient
improved compressibility
pharmaceutical excipient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA2183881A
Other languages
French (fr)
Other versions
CA2183881C (en
Inventor
Bob E. Sherwood
John N. Staniforth
Edward A. Hunter
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mendell Edward Co Inc
Original Assignee
Bob E. Sherwood
John N. Staniforth
Edward A. Hunter
Edward Mendell Co., Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23460251&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2183881(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bob E. Sherwood, John N. Staniforth, Edward A. Hunter, Edward Mendell Co., Inc. filed Critical Bob E. Sherwood
Publication of CA2183881A1 publication Critical patent/CA2183881A1/en
Application granted granted Critical
Publication of CA2183881C publication Critical patent/CA2183881C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A61K9/2036—Silicones; Polysiloxanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/724—Devices having flexible or movable element
    • Y10S977/727—Devices having flexible or movable element formed from biological material
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/773—Nanoparticle, i.e. structure having three dimensions of 100 nm or less
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/773—Nanoparticle, i.e. structure having three dimensions of 100 nm or less
    • Y10S977/775—Nanosized powder or flake, e.g. nanosized catalyst
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/788—Of specified organic or carbon-based composition
    • Y10S977/797—Lipid particle
    • Y10S977/798—Lipid particle having internalized material
    • Y10S977/799—Containing biological material
    • Y10S977/801—Drug
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/84—Manufacture, treatment, or detection of nanostructure
    • Y10S977/89—Deposition of materials, e.g. coating, cvd, or ald
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/84—Manufacture, treatment, or detection of nanostructure
    • Y10S977/895—Manufacture, treatment, or detection of nanostructure having step or means utilizing chemical property
    • Y10S977/896—Chemical synthesis, e.g. chemical bonding or breaking
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/906—Drug delivery
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/915—Therapeutic or pharmaceutical composition
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]

Abstract

A microcrystalline cellulose-based excipient having improved compressibility, whether utilized in direct compression, dry granulation or wet granulation formulations, is disclosed. The excipient is an agglomerate of microcrystalline cellulose particles and from about 0.1 % to about 20 % silicon dioxide particles, by weight of the microcrystalline cellulose, wherein the microcrystalline cellulose and silicon dioxide are in intimate association with each other. The silicon dioxide utilized in the novel excipient has a particle size from about 1 nanomoter to about 100 microns. Most preferably, the silicon dioxide is a grade of colloidal silicon dioxide.
CA002183881A 1995-01-09 1996-01-05 Pharmaceutical excipient having improved compressibility Expired - Lifetime CA2183881C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/370,576 1995-01-09
US08/370,576 US5585115A (en) 1995-01-09 1995-01-09 Pharmaceutical excipient having improved compressability
PCT/US1996/000660 WO1996021429A1 (en) 1995-01-09 1996-01-05 Pharmaceutical excipient having improved compressibility

Publications (2)

Publication Number Publication Date
CA2183881A1 true CA2183881A1 (en) 1996-07-18
CA2183881C CA2183881C (en) 2000-08-01

Family

ID=23460251

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002183881A Expired - Lifetime CA2183881C (en) 1995-01-09 1996-01-05 Pharmaceutical excipient having improved compressibility

Country Status (19)

Country Link
US (10) US5585115A (en)
EP (2) EP0752848B1 (en)
JP (1) JP3300364B2 (en)
KR (1) KR100332337B1 (en)
AT (3) ATE445391T1 (en)
AU (1) AU698667B2 (en)
BR (1) BR9605329B1 (en)
CA (1) CA2183881C (en)
DE (3) DE69627934T2 (en)
DK (1) DK0752848T3 (en)
ES (1) ES2199281T3 (en)
FI (1) FI118754B (en)
HU (1) HUP9602360A3 (en)
IL (1) IL116675A (en)
MX (1) MX9603745A (en)
NO (1) NO320533B1 (en)
PT (1) PT752848E (en)
TW (1) TW372874B (en)
WO (1) WO1996021429A1 (en)

Families Citing this family (220)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6482516B1 (en) * 1993-07-20 2002-11-19 Banner Pharmacaps, Inc. Enrobed tablet
US5585115A (en) * 1995-01-09 1996-12-17 Edward H. Mendell Co., Inc. Pharmaceutical excipient having improved compressability
US5948438A (en) * 1995-01-09 1999-09-07 Edward Mendell Co., Inc. Pharmaceutical formulations having improved disintegration and/or absorptivity
US6936277B2 (en) * 1995-01-09 2005-08-30 J. Rettenmaier & Soehne Gmbh & Co. Kg Pharmaceutical excipient having improved compressibility
US6106865A (en) * 1995-01-09 2000-08-22 Edward Mendell Co., Inc. Pharmaceutical excipient having improved compressibility
US6395303B1 (en) 1996-06-10 2002-05-28 Edward Mendell Co., Inc. Process for preparing a directly compressible solid dosage form containing microcrystalline cellulose
US6471994B1 (en) * 1995-01-09 2002-10-29 Edward Mendell Co., Inc. Pharmaceutical excipient having improved compressibility
BE1009856A5 (en) 1995-07-14 1997-10-07 Sandoz Sa Pharmaceutical composition in the form of a solid release including macrolide and a vehicle.
US5733578A (en) 1995-11-15 1998-03-31 Edward Mendell Co., Inc. Directly compressible high load acetaminophen formulations
US6391337B2 (en) 1995-11-15 2002-05-21 Edward Mendell Co., Inc. Directly compressible high load acetaminophen formulations
US6852336B2 (en) 1995-11-15 2005-02-08 J. Rettenmaier & Soehne Gmbh + Co. Kg Directly compressible high load acetaminophen formulations
JP4064476B2 (en) * 1996-03-29 2008-03-19 エラワン ファーマスーティカル リサーチ アンドラボラトリー カンパニー リミテッド Spherical agglomerated starch with silicon dioxide
DE69717816T2 (en) * 1996-05-14 2003-10-02 Procter & Gamble METHOD FOR PRODUCING A DETERGENT WITH A LOW BULK BULK WEIGHT BY AGGLOMERATION AND SUBSEQUENT DIELECTRICAL HEATING
US5989591A (en) * 1997-03-14 1999-11-23 American Home Products Corporation Rapamycin formulations for oral administration
FR2761266B1 (en) * 1997-03-28 1999-07-02 Sanofi Sa PHARMACEUTICAL COMPOSITION FORMED BY WET GRANULATION FOR THE ORAL ADMINISTRATION OF A DERIVATIVE OF N-PIPERIDINO-3- PYRAZOLECARBOXAMIDE, ITS SALTS AND THEIR SOLVATES
FI109088B (en) * 1997-09-19 2002-05-31 Leiras Oy Tablet and process for its preparation
FR2769854B1 (en) * 1997-10-21 2000-03-31 Prographarm Lab NEW PROCESS FOR OBTAINING MICROSPHERES AND THE PRODUCTS THUS PRODUCED
PE20000066A1 (en) * 1997-12-22 2000-02-09 Schering Corp SOLID DOSAGE FORMS OF ORALLY ADMINISTRABLE RIBAVIRIN AND MANUFACTURING PROCESS
US6232351B1 (en) 1998-05-22 2001-05-15 Amway Corporation Co-processed botanical plant composition
EA004311B1 (en) * 1998-06-11 2004-02-26 Фармация Энд Апджон Компани A pharmaceutical tablet composition of durable action
IT1301969B1 (en) * 1998-07-30 2000-07-20 Lisapharma Spa SUCRALPHATE DRY GRANULAR AND POROUS GEL PROCEDURE FOR ITS PREPARATION, AND SOLID PHARMACEUTICAL COMPOSITIONS THAT CONTAIN IT
US20020009478A1 (en) * 1998-08-24 2002-01-24 Douglas Joseph Dobrozsi Oral liquid mucoadhesive compositions
SA99191255B1 (en) 1998-11-30 2006-11-25 جي دي سيرل اند كو celecoxib compounds
US6465502B1 (en) * 1998-12-23 2002-10-15 Novartis Ag Additional therapeutic use
US20030026835A1 (en) * 1999-02-15 2003-02-06 Sumitomo Pharmaceuticals Company Limited Tablets disintegrating rapidly in the oral cavity
US20040258750A1 (en) * 1999-06-28 2004-12-23 Gerard Alaux Timed dual release dosage forms comprising a short acting hypnotic or a salt thereof
EP1064938A1 (en) * 1999-06-28 2001-01-03 Sanofi-Synthelabo Pharmaceutical dosage forms for controlled release producing at least a timed pulse
ES2165768B1 (en) 1999-07-14 2003-04-01 Almirall Prodesfarma Sa NEW DERIVATIVES OF QUINUCLIDINE AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM.
US6294198B1 (en) 1999-08-24 2001-09-25 Purepac Pharmaceutical Co. Pharmaceutical tablet formulation containing gabapentin with improved physical and chemical characteristics and method of making the same
US6656501B1 (en) 1999-09-01 2003-12-02 John T. Cooker Oral delivery system and method for making same
US20040101540A1 (en) * 1999-09-01 2004-05-27 John Cooker Oral delivery system and method for making same
CA2386312A1 (en) * 1999-09-29 2001-04-05 R.P. Scherer Technologies, Inc. Hydrolyzed cellulose granulations of salts of drugs
GB9924351D0 (en) 1999-10-14 1999-12-15 Brennan Frank Immunomodulation methods and compositions
KR101216270B1 (en) 1999-10-29 2012-12-31 유로-셀티크 소시에떼 아노뉨 Controlled release hydrocodone formulations
US10179130B2 (en) 1999-10-29 2019-01-15 Purdue Pharma L.P. Controlled release hydrocodone formulations
KR20020062323A (en) 1999-12-06 2002-07-25 펜웨스트 파머슈티칼즈 컴파니 Pharmaceutical superdisintegrant
US6793934B1 (en) * 1999-12-08 2004-09-21 Shire Laboratories, Inc. Solid oral dosage form
US6632429B1 (en) 1999-12-17 2003-10-14 Joan M. Fallon Methods for treating pervasive development disorders
US6399101B1 (en) 2000-03-30 2002-06-04 Mova Pharmaceutical Corp. Stable thyroid hormone preparations and method of making same
US6800297B2 (en) * 2000-06-15 2004-10-05 Acusphere, Inc. Porous COX-2 inhibitor matrices and methods of manufacture thereof
AT414205B (en) 2000-06-20 2006-10-15 Vis Vitalis Lizenz & Handels PROCESS FOR PRODUCING UNSATURATED FATTY ACID DRY CONCENTRATE
JP2002055277A (en) * 2000-08-11 2002-02-20 Nikon Corp Relay image-formation optical system, and illumination optical device and exposure device equipped with the optical system
US20070053895A1 (en) 2000-08-14 2007-03-08 Fallon Joan M Method of treating and diagnosing parkinsons disease and related dysautonomic disorders
AU2002227383B2 (en) 2000-10-30 2004-07-08 Euro-Celtique S.A. Controlled release hydrocodone formulations
US8030002B2 (en) * 2000-11-16 2011-10-04 Curemark Llc Methods for diagnosing pervasive development disorders, dysautonomia and other neurological conditions
AT5874U1 (en) * 2000-12-29 2003-01-27 Bioorg Bv PHARMACEUTICAL PREPARATIONS CONTAINING AMLODIPINMALEAT
US20030050312A1 (en) * 2001-03-12 2003-03-13 Hjorth Thyge Borup Novel tablets and capsules and a process for its preparation
JP2004529902A (en) 2001-03-13 2004-09-30 ペンウェスト ファーマシューティカルズ カンパニー Chronotherapeutic dosage forms containing glucocorticosteroids
US6761905B2 (en) 2001-05-01 2004-07-13 Wei Ming Pharmaceutical Mfg. Co., Ltd. Process for the preparation of direct tabletting formulations and aids
DE10126163A1 (en) * 2001-05-30 2002-12-05 Degussa Solid, semi-solid or liquid pharmaceutical or cosmetic preparations, containing pyrogenic silicon dioxide of high tamped density as auxiliary to provide good flow properties
US20030027848A1 (en) * 2001-06-15 2003-02-06 Anne Billotte Stabilized formulations
US7101573B2 (en) * 2001-09-28 2006-09-05 Mcneil-Pcc, Inc. Simethicone solid oral dosage form
US20040001886A1 (en) * 2001-10-17 2004-01-01 Dr. Reddy's Laboratories Limited Stabilized pharmaceutical formulations containing amlodipine maleate
US6933380B2 (en) 2001-10-19 2005-08-23 Yung-Zip Chemical Ind. Co., Ltd. Excipients containing low residual solvent and method for producing the same
DE10153078A1 (en) * 2001-10-30 2003-05-22 Degussa Use of granules based on pyrogenic silicon dioxide in pharmaceutical compositions
US7815936B2 (en) * 2001-10-30 2010-10-19 Evonik Degussa Gmbh Use of granular materials based on pyrogenically produced silicon dioxide in pharmaceutical compositions
US6635675B2 (en) 2001-11-05 2003-10-21 Cypress Bioscience, Inc. Method of treating chronic fatigue syndrome
US6602911B2 (en) 2001-11-05 2003-08-05 Cypress Bioscience, Inc. Methods of treating fibromyalgia
US6753017B2 (en) * 2001-11-07 2004-06-22 Jrs Pharma Lp Process for preparing dry extracts
US20030099699A1 (en) 2001-11-13 2003-05-29 Hanshew Dwight D. Storage stable thyroxine active drug formulations and methods for their production
US6645526B2 (en) * 2001-11-13 2003-11-11 Mylan Pharmaceuticals, Inc. Storage stable thyroxine active drug formulations and methods for their production
US20030206978A1 (en) * 2001-11-29 2003-11-06 Bob Sherwood Agglomerated particles including an active agent coprocessed with silicified microcrystalline cellulose
WO2003047551A1 (en) * 2001-11-29 2003-06-12 Penwest Pharmaceutical Company Agglomerated particles including an active agent coprocessed with silicified microcrystalline cellulose
US7179488B2 (en) * 2001-11-29 2007-02-20 Bob Sherwood Process for co-spray drying liquid herbal extracts with dry silicified MCC
JP2003238393A (en) * 2002-02-15 2003-08-27 Otsuka Pharmaceut Co Ltd Tablet with improved tableting property and method for producing the same
WO2003086343A2 (en) * 2002-04-05 2003-10-23 Cadila Healthcare Limited Fast disintegrating oral dosage forms
US6958161B2 (en) * 2002-04-12 2005-10-25 F H Faulding & Co Limited Modified release coated drug preparation
US20030235571A1 (en) * 2002-06-19 2003-12-25 Gabriel Gojon-Romanillos Systemic treatment of pathological conditions resulting from oxidative stress and/or redox imbalance
US8361514B2 (en) * 2002-06-19 2013-01-29 Nuevas Alternatives Naturales Thermafat, S.A.P.I. de C.V. Systemic treatment of pathological conditions resulting from oxidative stress and/or redox imbalance
SI21221A (en) * 2002-06-21 2003-12-31 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Quickly decomposable tablets
AU2003265481A1 (en) * 2002-09-04 2004-03-29 Southwest Research Institute Microencapsulation of oxygen or water sensitive materials
WO2004022601A2 (en) * 2002-09-05 2004-03-18 J. Rettenmaier & Soehne Gmbh + Co. Kg Compositions for industrial applications
PT1551372T (en) * 2002-09-20 2018-07-23 Alpharma Pharmaceuticals Llc Sequestering subunit and related compositions and metohds
US7005514B2 (en) * 2002-10-16 2006-02-28 International Paper Company Process for preparing microcrystalline cellulose
DE10250711A1 (en) * 2002-10-31 2004-05-19 Degussa Ag Pharmaceutical and cosmetic preparations
US20040086566A1 (en) * 2002-11-04 2004-05-06 Alpharma, Inc. Waxy matrix dosage forms
US20050038063A1 (en) * 2002-11-29 2005-02-17 Kenneth Newman Method of treating acute pain with unitary dosage form comprising ibuprofen and oxycodone
EP1575584A4 (en) * 2002-11-29 2006-02-01 Forest Laboratories Combination of ibuprofen and oxycodone for acute pain relief
US20040265375A1 (en) * 2003-04-16 2004-12-30 Platteeuw Johannes J. Orally disintegrating tablets
US7037405B2 (en) * 2003-05-14 2006-05-02 International Paper Company Surface treatment with texturized microcrystalline cellulose microfibrils for improved paper and paper board
US7497924B2 (en) * 2003-05-14 2009-03-03 International Paper Company Surface treatment with texturized microcrystalline cellulose microfibrils for improved paper and paper board
JP4226004B2 (en) * 2003-06-19 2009-02-18 富士通株式会社 Transmission power control method and apparatus
US7364755B2 (en) * 2003-07-07 2008-04-29 Synthon Ip Inc. Modified calcium phosphate excipient
CA2531486C (en) * 2003-07-11 2012-10-02 Antonio A. Albano Saquinavir mesylate oral dosage form
US7198653B2 (en) 2003-07-31 2007-04-03 Delavau Llc Calcium carbonate granulation
US7838029B1 (en) 2003-07-31 2010-11-23 Watson Laboratories, Inc. Mirtazapine solid dosage forms
US7390503B1 (en) 2003-08-22 2008-06-24 Barr Laboratories, Inc. Ondansetron orally disintegrating tablets
CA2538991A1 (en) * 2003-09-18 2005-03-31 Children's Medical Center Corporation Treatment of severe distal colitis
EP1678139B1 (en) * 2003-10-10 2011-08-31 Synhton B.V. Solid-state montelukast
US20050196439A1 (en) * 2003-10-24 2005-09-08 J. Rettenmaier & Soehne Gmbh + Co. Kg Process for co-spray drying agents with dry silicified MCC
JP2005232260A (en) * 2004-02-18 2005-09-02 Asahi Kasei Chemicals Corp Porous composite particle of cellulose inorganic compound
SI1566173T1 (en) * 2004-02-20 2006-12-31 Mattern Udo Pharmaceutical composition for oral application and method for preparing thereof
MY142989A (en) * 2004-03-10 2011-02-14 Bayer Schering Pharma Ag Stabilised supersaturated solids of lipophilic drugs
US20070196471A1 (en) * 2004-04-02 2007-08-23 Thosar Shilpa S Micronized Eplerenone Compositions
US7829716B2 (en) 2004-04-30 2010-11-09 Synthon Pharmaceuticals, Inc. Process for making montelukast and intermediates therefor
US7501517B2 (en) * 2004-04-30 2009-03-10 Synthon Ip, Inc. Process for making montelukast and intermediates therefor
WO2006002255A2 (en) * 2004-06-23 2006-01-05 Dr. Reddy's Laboratories Ltd. A pharmaceutical formulation of balaglitazone
BRPI0512900A (en) * 2004-06-30 2008-04-15 Albemarle Corp pharmaceutical composition comprising ibuprofen, process for preparing the ibuprofen-enriched granules and the dry granules made by this process
EP1773292B1 (en) * 2004-07-01 2009-03-11 LEK Pharmaceuticals D.D. Rapidly disintegrating orodispersible composition containing nonfilamentous coprocessed polyols particles and silicified microcrystalline cellulose
JP2008507362A (en) * 2004-07-22 2008-03-13 ヘモ ナノサイエンス リミテッド ライアビリティ カンパニー Compositions and methods for treating excessive bleeding
AU2005315291A1 (en) * 2004-12-13 2006-06-22 Mcneil-Ppc, Inc. Compositions and methods for stabilizing active pharmaceutical ingredients
TWI323741B (en) * 2004-12-16 2010-04-21 K C Tech Co Ltd Abrasive particles, polishing slurry, and producing method thereof
KR100641348B1 (en) * 2005-06-03 2006-11-03 주식회사 케이씨텍 Slurry for cmp and method of fabricating the same and method of polishing substrate
US20070036859A1 (en) * 2005-08-11 2007-02-15 Perry Ronald L Sustained release antihistamine and decongestant composition
WO2007020079A2 (en) * 2005-08-17 2007-02-22 Synthon B.V. Orally disintegratable simvastatin tablets
US20080058282A1 (en) 2005-08-30 2008-03-06 Fallon Joan M Use of lactulose in the treatment of autism
US20070116695A1 (en) * 2005-09-21 2007-05-24 Fallon Joan M Pharmaceutical preparations for attention deficit disorder, attention deficit hyperactivity disorder and other associated disorders
US7994220B2 (en) * 2005-09-28 2011-08-09 Cypress Bioscience, Inc. Milnacipran for the long-term treatment of fibromyalgia syndrome
HUE032640T2 (en) 2005-11-08 2017-10-30 Vertex Pharma Heterocyclic modulators of ATP-binding cassette transporters
WO2007059372A2 (en) * 2005-11-09 2007-05-24 St. Jude Children's Research Hospital Use of chloroquine to treat metabolic syndrome
US7811604B1 (en) 2005-11-14 2010-10-12 Barr Laboratories, Inc. Non-effervescent, orally disintegrating solid pharmaceutical dosage forms comprising clozapine and methods of making and using the same
AR056815A1 (en) * 2005-11-18 2007-10-24 Synthon Bv PROCESS TO PREPARE MONTELUKAST, INTERMEDIARIES OF THE SAME AND ITS ADDITION SALTS AND PROCEDURE OF PURIFICATION OF THESE AND MONTELUKAST
DE102005061965A1 (en) * 2005-12-23 2007-07-05 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Oxidic agglomerate particles, useful e.g. in the production of lacquers, colors, ink, coating systems, flame protection systems and/or electrical rheologic liquids, comprises agglomerated oxidic nano-scale primary particles
CN101432267A (en) * 2006-03-17 2009-05-13 斯索恩有限公司 Montelukast amantadine salt
MY149923A (en) * 2006-03-24 2013-10-31 Kowa Co Oral fast-disintegrating tablet
CA2687118A1 (en) * 2006-05-19 2007-12-13 Somaxon Pharmaceuticals, Inc. Methods of using low-dose doxepin for the improvement of sleep
US20100179215A1 (en) 2006-05-19 2010-07-15 Somaxon Pharmaceuticals, Inc. Doxepin isomers and isomeric mixtures and methods of using the same to treat sleep disorders
US20100227916A1 (en) * 2006-05-19 2010-09-09 Somaxon Pharmaceuticals, Inc N-desmethyl-doxepin and methods of using the same to treat sleep disorders
US20100179214A1 (en) * 2006-05-19 2010-07-15 Somaxon Pharmaceuticals, Inc. Doxepin trans isomers and isomeric mixtures and methods of using the same to treat sleep disorders
US20080058408A1 (en) 2006-05-19 2008-03-06 Rogowski Roberta L Low-dose doxepin for treatment of sleep disorders in elderly patients
US20070292508A1 (en) * 2006-06-05 2007-12-20 Balchem Corporation Orally disintegrating dosage forms
US20070281016A1 (en) * 2006-06-06 2007-12-06 Endo Pharmaceuticals Inc., A Delaware Corporation Sustained release oxycodone composition with acrylic polymer and surfactant
US20080069891A1 (en) 2006-09-15 2008-03-20 Cima Labs, Inc. Abuse resistant drug formulation
EP2526932B1 (en) 2006-06-19 2017-06-07 Alpharma Pharmaceuticals LLC Pharmaceutical composition
GB0612809D0 (en) * 2006-06-28 2006-08-09 Univ Sunderland Formulation
WO2008011150A1 (en) 2006-07-20 2008-01-24 Somaxon Pharmaceuticals, Inc. Methods of improving the pharmacokinetics of doxepin
WO2008018556A1 (en) * 2006-08-09 2008-02-14 Mitsubishi Tanabe Pharma Corporation Tablet
SA07280459B1 (en) 2006-08-25 2011-07-20 بيورديو فارما إل. بي. Tamper Resistant Oral Pharmaceutical Dosage Forms Comprising an Opioid Analgesic
US8124598B2 (en) * 2006-09-14 2012-02-28 Sharon Sageman 7-keto DHEA for psychiatric use
US9138414B1 (en) 2006-09-15 2015-09-22 Delavau Llc Calcium supplement having enhanced absorption
US8445018B2 (en) 2006-09-15 2013-05-21 Cima Labs Inc. Abuse resistant drug formulation
US20080081069A1 (en) * 2006-09-28 2008-04-03 Lupin Limited Novel controlled release formulations of divalproex sodium
US20080182890A1 (en) * 2006-10-04 2008-07-31 Somaxon Pharmaceuticals, Inc. Methods of using low-dose doxepin for the improvement of sleep
US8653066B2 (en) 2006-10-09 2014-02-18 Charleston Laboratories, Inc. Pharmaceutical compositions
JP2010506833A (en) * 2006-10-11 2010-03-04 アルファーマ，インコーポレイテッド Pharmaceutical composition
US20090148502A1 (en) * 2006-10-23 2009-06-11 Hemo Nanoscience, Llc Compositions and methods for treating lacerations, abrasions, avulsions, burns, ulcers, and cases of excessive bleeding
US20100105614A1 (en) 2006-10-25 2010-04-29 Somaxon Pharmaceuticals, Inc. Ultra low dose doxepin and methods of using the same to treat sleep disorders
WO2008057267A2 (en) * 2006-10-27 2008-05-15 Fmc Corporation Co-processed microcrystalline cellulose and sugar alcohol as an excipient for tablet formulations
EP2077850A2 (en) * 2006-10-31 2009-07-15 Achillion Pharmaceuticals, Inc. Elvucitabine pharmaceutical compositions
WO2008070795A2 (en) * 2006-12-06 2008-06-12 Somaxon Pharmaceuticals, Inc. Combination therapy using low-dose doxepin for the improvement of sleep
JP5290198B2 (en) * 2006-12-20 2013-09-18 ミラン ファーマシューティカルズ ユーエルシー Pharmaceutical composition comprising hot melt granulated lubricant
US20080167325A1 (en) * 2006-12-27 2008-07-10 Bs Praveen Kumar Valacyclovir compositions
EP3150586B1 (en) 2007-02-23 2020-01-08 Gilead Sciences, Inc. Modulators of pharmacokinetic properties of therapeutics
WO2008128115A2 (en) * 2007-04-13 2008-10-23 Somaxon Pharmaceuticals, Inc. Low-dose doxepin formulations
WO2008140772A2 (en) * 2007-05-08 2008-11-20 Hercules Incorporated Robust rapid disintegration tablet formulation
EP1997480A1 (en) * 2007-06-01 2008-12-03 The Jordanian Pharmaceutical Manufacturing Co. Mineral-fiber solid dispersion, method for preparing the same and use thereof as pharmaceutical tableting aid
US20100160274A1 (en) * 2007-09-07 2010-06-24 Sharon Sageman 7-KETO DHEA for Psychiatric Use
DE102007045686A1 (en) * 2007-09-24 2009-04-02 J. Rettenmaier & Söhne Gmbh + Co. Kg Process for the preparation of free-flowing, powdery extracts by means of the fluidized bed drying
US9198687B2 (en) * 2007-10-17 2015-12-01 Covidien Lp Acute stroke revascularization/recanalization systems processes and products thereby
CN101910156B (en) 2007-12-07 2013-12-04 沃泰克斯药物股份有限公司 Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3] dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid
EP2224808A4 (en) * 2007-12-17 2013-11-27 Alpharma Pharmaceuticals Llc Pharmaceutical composition
WO2009079521A1 (en) * 2007-12-17 2009-06-25 Alpharma Pharmaceuticals, Llc Pharmaceutical composition
US8623418B2 (en) * 2007-12-17 2014-01-07 Alpharma Pharmaceuticals Llc Pharmaceutical composition
US20100151014A1 (en) * 2008-12-16 2010-06-17 Alpharma Pharmaceuticals, Llc Pharmaceutical composition
US20100297225A1 (en) * 2007-12-20 2010-11-25 Pharmathen S.A. Sustained-release pharmaceutical formulation containing an antimuscarinic agent and a wetting agent as well as a process for the preparation thereof
EP2240022B1 (en) 2008-01-09 2016-12-28 Charleston Laboratories, Inc. Bilayered tablets comprising oxycodone and promethazine
EP2098119A1 (en) 2008-02-15 2009-09-09 Sara Lee/DE N.V. Sustained release insecticide composition
AU2009223061B2 (en) 2008-03-11 2014-10-09 Depomed Inc. Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
US8372432B2 (en) 2008-03-11 2013-02-12 Depomed, Inc. Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
US8658163B2 (en) 2008-03-13 2014-02-25 Curemark Llc Compositions and use thereof for treating symptoms of preeclampsia
EP2100599A1 (en) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
EP2100598A1 (en) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
US8084025B2 (en) 2008-04-18 2011-12-27 Curemark Llc Method for the treatment of the symptoms of drug and alcohol addiction
WO2009130056A1 (en) * 2008-04-25 2009-10-29 Synthon B.V. Process for making montelukast intermediates
CA2720856C (en) 2008-05-02 2016-02-02 Gilead Sciences, Inc. The use of solid carrier particles to improve the processability of a pharmaceutical agent
US9320780B2 (en) 2008-06-26 2016-04-26 Curemark Llc Methods and compositions for the treatment of symptoms of Williams Syndrome
PL2318035T3 (en) 2008-07-01 2019-10-31 Curemark Llc Methods and compositions for the treatment of symptoms of neurological and mental health disorders
US10776453B2 (en) 2008-08-04 2020-09-15 Galenagen, Llc Systems and methods employing remote data gathering and monitoring for diagnosing, staging, and treatment of Parkinsons disease, movement and neurological disorders, and chronic pain
AU2009279372A1 (en) 2008-08-06 2010-02-11 Gosforth Centre (Holdings) Pty Ltd Compositions and methods for treating psychiatric disorders
US20100092447A1 (en) 2008-10-03 2010-04-15 Fallon Joan M Methods and compositions for the treatment of symptoms of prion diseases
US8399513B2 (en) 2008-10-20 2013-03-19 Xenoport, Inc. Levodopa prodrug mesylate hydrate
CN102186804A (en) * 2008-10-20 2011-09-14 克塞诺波特公司 Methods of synthesizing a levodopa ester prodrug
BRPI1007379B8 (en) 2009-01-06 2022-07-19 Curemark Llc pharmaceutical compositions for the treatment or prevention of oral infections by e. coli
CA2747611C (en) 2009-01-06 2019-09-17 Curemark Llc Compositions and methods for the treatment or prevention of staphylococcus aureus infections and for the eradication or reduction of staphylococcus aureus on surfaces
US20120077888A1 (en) 2009-03-26 2012-03-29 Royal College Of Surgeons In Ireland Orodispersible tablets
US9056050B2 (en) 2009-04-13 2015-06-16 Curemark Llc Enzyme delivery systems and methods of preparation and use
US20100285164A1 (en) * 2009-05-11 2010-11-11 Jrs Pharma Orally Disintegrating Excipient
EP2253306A1 (en) 2009-05-18 2010-11-24 Royal College of Surgeons in Ireland Orodispersible dosage forms containing solid drug dispersions
WO2011006012A1 (en) 2009-07-08 2011-01-13 Charleston Laboratories Inc. Pharmaceutical compositions
AU2010279171A1 (en) * 2009-07-28 2012-03-01 Takeda Pharmaceutical Company Limited Tablet
US20120214820A1 (en) 2009-09-15 2012-08-23 Ratiopharm Gmbh Orally disintegrating pharmaceutical dosage form containing aripiprazole
WO2011050135A1 (en) 2009-10-21 2011-04-28 Curemark Llc Methods and compositions for the prevention and treatment of influenza
TWI461213B (en) * 2009-11-05 2014-11-21 Fmc Corp Microcrystalline cellulose and calcium phosphate compositions useful as pharmaceutical excipients
AU2010315892B2 (en) * 2009-11-09 2014-09-18 Xenoport, Inc. Pharmaceutical compositions and oral dosage forms of a levodopa prodrug and methods of use
US20110144211A1 (en) * 2009-12-11 2011-06-16 Lars Hermann Use of microcrystalline cellulose for interfering with the extraction of ephedrine
US8597681B2 (en) 2009-12-22 2013-12-03 Mallinckrodt Llc Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
US9198861B2 (en) 2009-12-22 2015-12-01 Mallinckrodt Llc Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
SI3150198T1 (en) 2010-04-07 2021-11-30 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions of 3-(6-(1-(2,2-difluorobenzo(d)(1,3)dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyriodin-2-yl)benzoic acid and administration thereof
MX2012012991A (en) 2010-05-11 2012-11-30 Cima Labs Inc Alcoholres i stant metoprolol - containing extended - release oral dosage forms.
HU1000278D0 (en) * 2010-05-28 2010-07-28 Egis Gyogyszergyar Nyilvanosan Novel pharmaceutical use uf silicic acid
JP5759457B2 (en) 2010-06-29 2015-08-05 旭化成ケミカルズ株式会社 Composite particles containing cellulose and inorganic compounds
US20140141090A1 (en) 2011-02-02 2014-05-22 Edward S. Wilson Pharmaceutical Composition Comprising Opioid Agonist And Sequestered Antagonist
DE102011010437A1 (en) * 2011-02-04 2012-08-09 J. Rettenmaier & Söhne Gmbh + Co. Kg Tableting aids
BR112013022431B1 (en) 2011-04-06 2019-10-08 Dow Global Technologies Llc Polysaccharide derivative, dosage form, process for preparing a dosage form and use of a polysaccharide derivative
EP2510928A1 (en) 2011-04-15 2012-10-17 Almirall, S.A. Aclidinium for use in improving the quality of sleep in respiratory patients
GB2503852B (en) 2011-04-21 2018-12-12 Curemark Llc Compounds for the treatment of neuropsychiatric disorders
US8858963B1 (en) 2011-05-17 2014-10-14 Mallinckrodt Llc Tamper resistant composition comprising hydrocodone and acetaminophen for rapid onset and extended duration of analgesia
US8741885B1 (en) 2011-05-17 2014-06-03 Mallinckrodt Llc Gastric retentive extended release pharmaceutical compositions
US9050335B1 (en) 2011-05-17 2015-06-09 Mallinckrodt Llc Pharmaceutical compositions for extended release of oxycodone and acetaminophen resulting in a quick onset and prolonged period of analgesia
GB201111712D0 (en) 2011-07-08 2011-08-24 Gosforth Ct Holdings Pty Ltd Pharmaceutical compositions
ES2545337T3 (en) * 2011-07-19 2015-09-10 Pantarhei Bioscience B.V. Tablet containing dehydroepiandrosterone (DHEA)
US10350278B2 (en) 2012-05-30 2019-07-16 Curemark, Llc Methods of treating Celiac disease
ES2738182T3 (en) 2013-03-12 2020-01-20 Hercules Llc Polypropylene Coated Silica Coated Composition
US9675587B2 (en) 2013-03-14 2017-06-13 Allergan Holdings Unlimited Company Opioid receptor modulator dosage formulations
CO7150300A1 (en) * 2013-06-27 2014-12-29 Univ Antioquia Production of a new multipurpose agglomerated cellulosic excipient
US10231932B2 (en) 2013-11-12 2019-03-19 Vertex Pharmaceuticals Incorporated Process of preparing pharmaceutical compositions for the treatment of CFTR mediated diseases
WO2015073736A1 (en) 2013-11-13 2015-05-21 Arbor Pharmaceuticals, Llc Methods and compositions for treating adhd
EP2907498A1 (en) * 2014-02-13 2015-08-19 Induchem Ag Exfoliating cellulose beads and cosmetic uses thereof
KR101665970B1 (en) * 2015-01-06 2016-10-13 주식회사이-글벳 Method for Producing Ketoconazole Tablets
CN104771761A (en) * 2015-03-19 2015-07-15 深圳国源国药有限公司 Novel pharmaceutical auxiliary material namely silicified microcrystalline cellulose and preparation method thereof
WO2016201119A1 (en) * 2015-06-09 2016-12-15 J. Rettenmaier & Söhne Gmbh + Co Kg Excipient and oral solid dosage forms for oily drugs
US10166185B2 (en) 2015-06-09 2019-01-01 J. Rettenmaier & Söhne Gmbh + Co Kg Excipient and oral solid dosage forms for oily drugs
US20180362974A1 (en) 2015-07-02 2018-12-20 University Of Louisville Research Foundation, Inc. EDIBLE PLANT-DERIVED MICROVESICLE COMPOSITIONS FOR DELIVERY OF miRNA AND METHODS FOR TREATMENT OF CANCER
CA2937365C (en) 2016-03-29 2018-09-18 F. Hoffmann-La Roche Ag Granulate formulation of 5-methyl-1-phenyl-2-(1h)-pyridone and method of making the same
US10751288B2 (en) 2016-08-23 2020-08-25 New Jersey Institute Of Technology Dry processed surface coated engineering excipients
CN107583055A (en) * 2017-09-01 2018-01-16 山东聊城阿华制药股份有限公司 A kind of microcrystalline cellulose silica pre-mixing agent preparation method
WO2021076218A1 (en) * 2019-10-18 2021-04-22 Weinberg Assa Methods for prevention and treatment of fibromyalgia by contact vasodilators
US11541009B2 (en) 2020-09-10 2023-01-03 Curemark, Llc Methods of prophylaxis of coronavirus infection and treatment of coronaviruses
US11925707B2 (en) 2021-03-15 2024-03-12 Jrs Pharma Gmbh & Co. Kg Co-processed lubricant:MCG for tablets
CN113968584B (en) * 2021-10-28 2022-05-27 金三江(肇庆)硅材料股份有限公司 Hollow spherical silicon dioxide and preparation method thereof

Family Cites Families (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3023104A (en) * 1960-07-05 1962-02-27 American Viscose Corp Food compositions incorporating cellulose crystallite aggregates
US3067037A (en) * 1960-12-02 1962-12-04 American Viscose Corp Foamable products containing disintegrated cellulose crystallite aggregates
US3141875A (en) * 1961-03-15 1964-07-21 Fmc Corp Crystallite aggregates disintegrated in acid medium
US3573058A (en) * 1967-01-30 1971-03-30 Swift & Co Microcrystalline cellulose compositions co-dried with hydrocolloids
US3539365A (en) * 1967-02-13 1970-11-10 Fmc Corp Dispersing and stabilizing agent comprising beta-1,4 glucan and cmc and method for its preparation
US3696188A (en) * 1971-06-16 1972-10-03 Schering Corp Laminated tablets
DE2416903A1 (en) * 1974-04-06 1975-10-09 Bayer Ag USE OF MELT-SPRAYED BALL-SHAPED PHENACETIN GRANULES FOR THE MANUFACTURING OF TABLETS IN THE DIRECT TABLET PROCESS
DE2446058A1 (en) * 1974-09-26 1976-04-08 Henning Berlin Gmbh GALENIC PREPARATION FOR ALLOPURINOL CONTINUOUS THERAPY
US4156021A (en) * 1976-03-03 1979-05-22 Maxfibe, Inc. Oleaginous fibrous simulated food product
US4109018A (en) * 1976-05-27 1978-08-22 Thompson Jerome B Low calorie diet bread
US4143163A (en) * 1976-06-30 1979-03-06 Maxfibe, Inc. Coated fibrous cellulose product and process
AU508480B2 (en) * 1977-04-13 1980-03-20 Asahi Kasei Kogyo Kabushiki Kaisha Microcrystalline cellulose excipient and pharmaceutical composition containing thesame
US4219580A (en) * 1978-06-29 1980-08-26 Pfizer Inc. Flour substitutes
US4232052A (en) * 1979-03-12 1980-11-04 National Starch And Chemical Corporation Process for powdering high fat foodstuffs
US4395422A (en) * 1981-04-06 1983-07-26 Basf Wyandotte Corporation Spray dried vitamin E powder
US4664915A (en) * 1981-07-01 1987-05-12 Bristol-Myers Company Compressed and formed alkaline component suitable for use in buffered aspirin product
US4923981A (en) * 1982-09-03 1990-05-08 Sbp, Inc. Use of parenchymal cell cellulose to improve comestibles
DE3306366A1 (en) * 1983-02-24 1984-08-30 Bayer Ag, 5090 Leverkusen MEDICINAL PRODUCTS CONTAINING MUZOLIMIN, THE USE THEREOF AND METHOD FOR THE PRODUCTION THEREOF
US4533674A (en) * 1983-10-24 1985-08-06 Basf Wyandotte Corporation Process for preparing a sugar and starch free spray-dried vitamin C powder containing 90 percent ascorbic acid
DK148784D0 (en) * 1984-02-29 1984-02-29 Nexus Aps POWDER PRODUCTS
US4721709A (en) * 1984-07-26 1988-01-26 Pyare Seth Novel pharmaceutical compositions containing hydrophobic practically water-insoluble drugs adsorbed on pharmaceutical excipients as carrier; process for their preparation and the use of said compositions
CA1261261A (en) * 1985-03-08 1989-09-26 Dev K. Mehra Coprocessed microcrystalline cellulose and calcium carbonate composition and its preparation
US4744987A (en) * 1985-03-08 1988-05-17 Fmc Corporation Coprocessed microcrystalline cellulose and calcium carbonate composition and its preparation
IT1188212B (en) * 1985-12-20 1988-01-07 Paolo Colombo SYSTEM FOR THE RELEASE SPEED OF ACTIVE SUBSTANCES
US4849227A (en) * 1986-03-21 1989-07-18 Eurasiam Laboratories, Inc. Pharmaceutical compositions
US4810516A (en) * 1987-02-27 1989-03-07 The Procter & Gamble Company Reduced calorie and reduced fat chocolate confectionery compositions
US4814195A (en) * 1987-03-20 1989-03-21 Winters Canning Co. Reduced calorie peanut butter product
US4786503A (en) * 1987-04-06 1988-11-22 Alza Corporation Dosage form comprising parallel lamine
US5200193A (en) * 1987-04-22 1993-04-06 Mcneilab, Inc. Pharmaceutical sustained release matrix and process
US4820522A (en) * 1987-07-27 1989-04-11 Mcneilab, Inc. Oral sustained release acetaminophen formulation and process
US5019397A (en) * 1988-04-21 1991-05-28 Alza Corporation Aqueous emulsion for pharmaceutical dosage form
US4910023A (en) * 1988-06-09 1990-03-20 Warner-Lambert Company Drug in combination with flavor masking agent and method for making same
US4980193A (en) * 1988-06-17 1990-12-25 Fmx Corporation Microcrystalline cellulose-based stabilizer system for dry mix instant chocolate drink
US4911946A (en) * 1988-06-24 1990-03-27 The Nutra Sweet Company Carbohydrate cream substitute
GB8829088D0 (en) * 1988-12-13 1989-01-25 Smith Kline French Lab Compounds
US5011701A (en) * 1988-12-30 1991-04-30 Kraft General Foods, Inc. Low calorie food products having smooth, creamy, organoleptic characteristics
US5026569A (en) * 1989-01-18 1991-06-25 The Procter & Gamble Company Cotton fiber particles for use in baked goods
US5126145A (en) * 1989-04-13 1992-06-30 Upsher Smith Laboratories Inc Controlled release tablet containing water soluble medicament
EP0458484A3 (en) * 1989-05-26 1992-12-09 The Kendall Company Rubber-based adhesive tapes
RU2082299C1 (en) * 1989-05-26 1997-06-27 Фмк Корпорейшн Fat-like filling agent and a method of its preparing
DK161743C (en) * 1989-07-03 1992-02-17 Niro Atomizer As PROCEDURE AND APPARATUS FOR AGGLOMERATION OF A POWDER-SHAPED MATERIAL
IL96311A (en) * 1989-12-01 1995-05-26 Abbott Lab Sustained-release drug dosage units
US5158798A (en) * 1990-02-05 1992-10-27 Pfizer Inc. Low-calorie fat substitute
US5075115A (en) * 1990-04-02 1991-12-24 Fmc Corporation Process for polymerizing poly(lactic acid)
USH1229H (en) * 1990-07-18 1993-09-07 Fmc Corporation Stabilizing agent for dry mix food products
HU206824B (en) * 1990-08-24 1993-01-28 Biogal Gyogyszergyar Process for the production of a table crystallizing in the monoclinic system, which contains light-, heat-, and moisture- sensitive active agents
EP0567541B1 (en) * 1991-01-16 1998-10-07 Fmc Corporation Carrier for active agents, and solid dosage forms prepared therewith
US5132128A (en) * 1991-04-17 1992-07-21 The J. M. Smucker Company Reduced calorie dessert topping
US5162117A (en) * 1991-11-22 1992-11-10 Schering Corporation Controlled release flutamide composition
US5209942A (en) * 1991-11-27 1993-05-11 Thomas J. Lipton, Co., Division Of Conopco, Inc. Low fat/no fat salad dressing having mimetic functional properties fat and a process therefor
ATE196733T1 (en) * 1991-12-30 2000-10-15 Fmc Corp COMPOSITION BASED ON MICROCRYSTALLINE CELLULOSE FOR THE PRODUCTION OF SPHERICAL PARTICLES
KR950703016A (en) * 1992-08-20 1995-08-23 미리암디. 메코나헤어 CROSSLINKED POLYMERIC AMMONIUM SALTS
JP3094234B2 (en) * 1992-09-22 2000-10-03 エフ エム シー コーポレーション Microcrystalline cellulose product and method for producing the same
US5338562A (en) * 1992-11-25 1994-08-16 Fmc Corporation Low fat spread and process for making same
TW260612B (en) * 1993-01-05 1995-10-21 Asahi Chemical Ind
DE4303846A1 (en) * 1993-02-10 1994-08-11 Merck Patent Gmbh Process for the preparation of a tablet containing S-ibuprofen
US5366742A (en) * 1993-05-03 1994-11-22 Fmc Corporation Colloidal microcrystalline cellulose and barrier dispersant composition and method for manufacture
US5441753A (en) * 1994-01-28 1995-08-15 Fmc Corporation Coprocessed particulate bulking and formulating AIDS: their composition, production, and use
US5505982A (en) * 1994-01-28 1996-04-09 Fmc Corporation Chocolate confection
DE4406073A1 (en) 1994-02-24 1995-08-31 Univ Ludwigs Albert Process for the production of human, clonogenic fibroblasts, process for gene transfection of fibroblasts and fibroblasts obtained in this way
US5462761A (en) * 1994-04-04 1995-10-31 Fmc Corporation Microcrystalline cellulose and glucomannan aggregates
US5447729A (en) * 1994-04-07 1995-09-05 Pharmavene, Inc. Multilamellar drug delivery systems
IT1270239B (en) * 1994-06-17 1997-04-29 Zambon Spa SOLID PHARMACEUTICAL COMPOSITION CONTAINING ACID (S) -2- (4- ISOBUTYLPHENYL) PROPIONIC AS ACTIVE INGREDIENT
US5429830A (en) * 1994-07-08 1995-07-04 Fmc Corporation Marshmallow-type confections
US5585115A (en) * 1995-01-09 1996-12-17 Edward H. Mendell Co., Inc. Pharmaceutical excipient having improved compressability
US6471994B1 (en) 1995-01-09 2002-10-29 Edward Mendell Co., Inc. Pharmaceutical excipient having improved compressibility
US6106865A (en) * 1995-01-09 2000-08-22 Edward Mendell Co., Inc. Pharmaceutical excipient having improved compressibility
US5948438A (en) 1995-01-09 1999-09-07 Edward Mendell Co., Inc. Pharmaceutical formulations having improved disintegration and/or absorptivity
IL116674A (en) * 1995-01-09 2003-05-29 Mendell Co Inc Edward Microcrystalline cellulose-based excipient having improved compressibility, pharmaceutical compositions containing the same and methods for the preparation of said excipient and of solid dosage form thereof
US6395303B1 (en) 1996-06-10 2002-05-28 Edward Mendell Co., Inc. Process for preparing a directly compressible solid dosage form containing microcrystalline cellulose
US5733578A (en) 1995-11-15 1998-03-31 Edward Mendell Co., Inc. Directly compressible high load acetaminophen formulations
US5858409A (en) 1996-04-17 1999-01-12 Fmc Corporation Hydrolyzed cellulose granulations for pharmaceuticals

Also Published As

Publication number Publication date
US20030096005A1 (en) 2003-05-22
EP0752848B1 (en) 2003-05-07
FI118754B (en) 2008-03-14
KR100332337B1 (en) 2002-11-11
DE69627934T2 (en) 2004-02-12
ATE239450T1 (en) 2003-05-15
JP3300364B2 (en) 2002-07-08
NO963732L (en) 1996-11-08
AU4759896A (en) 1996-07-31
US5585115A (en) 1996-12-17
IL116675A0 (en) 1996-05-14
BR9605329A (en) 1997-09-16
MX9603745A (en) 1997-07-31
US6358533B2 (en) 2002-03-19
ATE441403T1 (en) 2009-09-15
US6521261B2 (en) 2003-02-18
ATE445391T1 (en) 2009-10-15
US6858231B2 (en) 2005-02-22
PT752848E (en) 2003-08-29
DE69638054D1 (en) 2009-11-26
WO1996021429A1 (en) 1996-07-18
US5725883A (en) 1998-03-10
DE69627934D1 (en) 2003-06-12
AU698667B2 (en) 1998-11-05
HUP9602360A3 (en) 2001-12-28
NO320533B1 (en) 2005-12-19
CA2183881C (en) 2000-08-01
US5725884A (en) 1998-03-10
EP1287823B1 (en) 2009-09-02
NO963732D0 (en) 1996-09-06
HUP9602360A2 (en) 1997-08-28
DE69638015D1 (en) 2009-10-15
US6103219A (en) 2000-08-15
JPH10500426A (en) 1998-01-13
EP1287823A1 (en) 2003-03-05
US20050013861A1 (en) 2005-01-20
ES2199281T3 (en) 2004-02-16
DK0752848T3 (en) 2003-09-01
HU9602360D0 (en) 1996-11-28
BR9605329B1 (en) 2010-02-23
US20010001664A1 (en) 2001-05-24
FI963497A0 (en) 1996-09-06
FI963497A (en) 1996-11-06
EP0752848A1 (en) 1997-01-15
MX9603746A (en) 1997-07-31
US20020142032A1 (en) 2002-10-03
EP0752848A4 (en) 1998-11-04
TW372874B (en) 1999-11-01
US20090169621A1 (en) 2009-07-02
IL116675A (en) 2000-10-31
US6217909B1 (en) 2001-04-17

Similar Documents

Publication Publication Date Title
CA2183881A1 (en) Pharmaceutical Excipient Having Improved Compressibility
CA2183882A1 (en) Pharmaceutical Excipient Having Improved Compressibility
AU5462998A (en) Co-processed microcrystalline cellulose and calcium carbonate
NZ332659A (en) pharmaceutical compositions containing particles of tetrahydrolipstatin with a stabilizer and an excipient
AU1063799A (en) Taste masked pharmaceutical compositions
CA2112651A1 (en) Excipient Having High Compactability and Process for Preparing Same
CA2152795A1 (en) Readily available konjac glucomannan sustained release excipient
EP1036799A4 (en) Cellulose dispersion
CA2166891A1 (en) Method for making freeze dried drug dosage forms
CA2229351A1 (en) Free-flowing dried particles
CA2288958A1 (en) Pharmaceutical preparation comprising lyophilized liposomes encapsulating an active principle which is highly insoluble in water, and the process for preparing the said preparation
CA2045680A1 (en) High ibuprofen content granulations
RU98104417A (en) COMBINED OSMOTIC AND VOLUME-FORMING LIABILITIES
CA2176223A1 (en) Fenbendazole formulations
AU640725B2 (en) Spray drying process for making pharmaceutical powder compositions directly compressible into tablets
CA2352542A1 (en) Method for producing medicaments from plant extracts, in a solid form of administration
CA2454449A1 (en) Synergistic filler composition of pvp-va and silicified mycrocrystalline cellulose for tablet dosage form
RU95117578A (en) MEDICINAL PREVENTIVE MEANS
JPS5630914A (en) Preparation of hard capsule of chinese herbal remedy
CA2207334A1 (en) Sustained-release granular preparations and production process thereof
HUP9903767A2 (en) Hydrolyzed cellulose granulations for preparing pharmaceuticals
RU98115790A (en) METHOD FOR PRODUCING RANITIDINE TABLETS

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20160105